Fact CheckerSign in

NCT06103370Recruiting

Syringe Service Based Telemedicine and Social Network Driven HIV Prevention Service Implementation

Source: ClinicalTrials.gov · Last updated 10 Nov 2025

Brief summary (registry, in English)

The goal of this clinical trial is to evaluate the effectiveness of a social network intervention to recruit people who inject drugs and their networks for HIV testing and linkage to HIV prevention and treatment services in Maryland. Study aims are to determine the effectiveness of a social network driven intervention to increase: * HIV testing (primary); * PrEP knowledge; * Uptake of HIV services and pre-exposure prophylaxis (PrEP); * Uptake of medication for opioid use disorder (MOUD) initiation. Eligible participants who access syringe service programs (SSPs) serving two counties in Maryland and their risk network members (NMs) will be recruited using an established network inventory and coupon recruitment method. When an index successfully recruits NMs, the index-NM cluster will be randomized to either a peer-educator intervention arm or an equal-attention control arm. Index participants randomized to the peer-educator intervention arm will complete a training program adapted with stakeholder input to context that emphasizes effective communication, frequent HIV testing, and awareness of evidence-based HIV prevention and treatment services. An important innovation to the network intervention will be training indexes to use and distribute HIV self-test kits and naloxone to their NMs. Index participants randomized to the equal-attention control arm will receive training sessions focused on the opioid overdose epidemic and will not include any training to serve as a peer educator. All participants (indexes and NMs) will complete study assessments at baseline and at 3 and 9 months. We will compare the peer-educator intervention group and the equal-attention control group on rates of HIV testing, knowledge of PrEP options and resources, and rates of initiation of HIV treatment, PrEP, and MOUD treatment since the previous assessment (past 3 or 6 months).

Status (registry)
Recruiting
Study type
Interventional
Enrollment
360 (estimated)
First submitted
23 Oct 2023
Start date
Oct 2025
Primary completion date
Nov 2028
Lead sponsor
Johns Hopkins University
Diseases
HIV
NCT number
NCT06103370

What you commit to

  • Study type: Interventional
  • Planned participants: 360
  • From Oct 2025 to the primary completion date, Nov 2028
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Individuals lacking the capacity to consent

Who the study is looking for

  • Aged 18 or older
  • Self-reported injection drug use in the prior month
  • Accessed services at the SSP in the prior 3 months
  • Willing to undergo training and attend weekly booster group sessions
  • Able to recruit at least 1 drug use Network Member (NM) into study
  • Willing to talk with peers about PWID topics such as HIV prevention and care
  • Not previously enrolled in the study as index or NM
  • English-speaking
  • Aged 18 or older
  • Self-reported injection drug use in the prior month
  • Have a valid coupon or able to recall the 3-digit ID number
  • Not previously enrolled in the study as index or NM
  • English-speaking

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Johns Hopkins Hospital
Coordinator of this site? Confirm its status
BaltimoreUnited StatesNot yet recruiting
Frederick County Health Department, Street Safe Program
Coordinator of this site? Confirm its status
FrederickUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.